FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

10 letters match. Newest first.

  1. Kath Khemicals LLC

    FDA: Kath Khemicals, an OTC hand soap maker in Macomb, MI, released drugs without finished-product or glycerin identity testing.

    High risk
  2. Laboratoire Druide Inc.

    FDA warned Laboratoire Druide that its OTC drugs are adulterated because of inadequate glycerin identity testing, system validation and cleaning.

    High risk
  3. Eurosirel S.P.A

    FDA warns Eurosirel over CGMP failures in topical drugs and pain patches, including missing glycerin identity testing.

    High risk
  4. Seoul Cosmetics Co., Ltd.

    FDA warned Seoul Cosmetics, a South Korean drug maker, over poor manufacturing quality and unapproved OTC drugs.

    High risk
  5. Avaria Health & Beauty Corp.

    FDA cites Avaria Health & Beauty for manufacturing-rule violations in OTC drugs, including missing glycerin identity testing and weak quality unit.

    High risk
  6. Tan Alize Kozmetik Ve Temizlik Urunleri

    FDA warns Turkish OTC drug maker Tan Alize over missing glycerin identity testing and a weak quality unit; import alert issued.

    High risk
  7. NeilMed Pharmaceuticals Inc.

    FDA warned NeilMed Pharmaceuticals that its OTC drug manufacturing had current good manufacturing practice violations, including missing glycerin identity testing and dirty equipment.

    High risk
  8. Champaklal Maganlal Homeo Pharmacy Private Limited

    FDA says Champaklal Maganlal Homeo Pharmacy's Bebelyn diarrhea and colic products are unapproved new drugs for infants.

    High risk
  9. Champaklal Maganlal Homeo Pharmacy Private Limited

    Champaklal Maganlal Homeo Pharmacy failed to test each glycerin lot for identity, including DEG/EG, in OTC and homeopathic drugs.

    High risk
  10. Professional Compounding Centers of America dba PCCA

    PCCA received adulterated drug ingredients from suppliers on FDA import alerts and failed adequate glycerin identity testing.

    High risk